evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

30 questions · 32 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 5 · 15.6%GRADE not reported 0 · 0%Very low 12 · 37.5%Low 11 · 34.4%Moderate 4 · 12.5%High 0 · 0%

Infliximab 5–10 mg/kg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review